Last reviewed · How we verify

hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors — Treatment Landscape & Competitive Intelligence

hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Alhemo CONCIZUMAB Novo Nordisk Inc Tissue Factor Pathway Inhibitor Antagonist [EPC] 2024-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Novo Nordisk Inc · 1 drug in hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors:

Cite this brief

Drug Landscape (2026). hemophilia A (congenital factor VIII deficiency) with or without FVIII inhibitors — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hemophilia-a-congenital-factor-viii-deficiency-with-or-without-fviii-inhibitors. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing